{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T03:07:07Z","timestamp":1780628827714,"version":"3.54.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1007\/s13555-024-01302-0","type":"journal-article","created":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T16:05:03Z","timestamp":1730477103000},"page":"3133-3147","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Long-Term Efficacy and Safety of Bimekizumab and Other Biologics in Moderate to Severe Plaque Psoriasis: Updated Systematic Literature Review and Network Meta-analysis"],"prefix":"10.1007","volume":"14","author":[{"given":"Richard B.","family":"Warren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry","family":"Donnelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep","family":"Kiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Taieb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Slim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle","family":"Fahrbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binod","family":"Neupane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marissa","family":"Betts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0064-8707","authenticated-orcid":false,"given":"April","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,1]]},"reference":[{"key":"1302_CR1","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/S0140-6736(07)61128-3","volume":"3709583","author":"CE Griffiths","year":"2007","unstructured":"Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet. 2007;3709583:263\u201371. https:\/\/doi.org\/10.1016\/S0140-6736(07)61128-3.","journal-title":"Lancet"},{"key":"1302_CR2","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1001\/jamadermatol.2021.2007","volume":"1578","author":"AW Armstrong","year":"2021","unstructured":"Armstrong AW, Mehta MD, Schupp CW, Gondo GC, Bell SJ, Griffiths CEM. Psoriasis prevalence in adults in the United States. JAMA Dermatol. 2021;1578:940\u20136. https:\/\/doi.org\/10.1001\/jamadermatol.2021.2007.","journal-title":"JAMA Dermatol"},{"key":"1302_CR3","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m1590","volume":"369","author":"R Parisi","year":"2020","unstructured":"Parisi R, Iskandar IYK, Kontopantelis E, Augustin M, Griffiths CEM, Ashcroft DM. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ. 2020;369: m1590. https:\/\/doi.org\/10.1136\/bmj.m1590.","journal-title":"BMJ"},{"key":"1302_CR4","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.jaad.2010.11.055","volume":"651","author":"A Menter","year":"2011","unstructured":"Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J Am Acad Dermatol. 2011;651:137\u201374.","journal-title":"J Am Acad Dermatol"},{"key":"1302_CR5","doi-asserted-by":"publisher","first-page":"39","DOI":"10.2147\/btt.S252578","volume":"15","author":"ND Brownstone","year":"2021","unstructured":"Brownstone ND, Hong J, Mosca M, et al. Biologic treatments of psoriasis: an update for the clinician. Biologics. 2021;15:39\u201351. https:\/\/doi.org\/10.2147\/btt.S252578.","journal-title":"Biologics"},{"key":"1302_CR6","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.jaad.2023.08.097","volume":"901","author":"B Strober","year":"2024","unstructured":"Strober B, Ferris L, Callis Duffin K, et al. Real-world effectiveness of risankizumab in patients with moderate-to-severe psoriasis using the CorEvitas Psoriasis Registry. J Am Acad Dermatol. 2024;901:82\u201390. https:\/\/doi.org\/10.1016\/j.jaad.2023.08.097.","journal-title":"J Am Acad Dermatol"},{"key":"1302_CR7","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1038\/nature05663","volume":"4457130","author":"MA Lowes","year":"2007","unstructured":"Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature. 2007;4457130:866\u201373. https:\/\/doi.org\/10.1038\/nature05663.","journal-title":"Nature"},{"issue":"277\u201386","key":"1302_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.03.037","volume":"792","author":"KA Papp","year":"2018","unstructured":"Papp KA, Merola JF, Gottlieb AB, et al. Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: results from BE\u00a0ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase\u00a02b trial. J Am Acad Dermatol. 2018;792(277\u201386): e10. https:\/\/doi.org\/10.1016\/j.jaad.2018.03.037.","journal-title":"J Am Acad Dermatol"},{"key":"1302_CR9","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/S0140-6736(21)00125-2","volume":"39710273","author":"K Reich","year":"2021","unstructured":"Reich K, Papp KA, Blauvelt A, et al. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE\u00a0VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase\u00a03 trial. Lancet. 2021;39710273:487\u201398. https:\/\/doi.org\/10.1016\/S0140-6736(21)00125-2.","journal-title":"Lancet"},{"key":"1302_CR10","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.3389\/fimmu.2020.01894","volume":"11","author":"R Adams","year":"2020","unstructured":"Adams R, Maroof A, Baker T, et al. Bimekizumab, a novel humanized IgG1 antibody that neutralizes both IL-17A and IL-17F. Front Immunol. 2020;11:1894. https:\/\/doi.org\/10.3389\/fimmu.2020.01894.","journal-title":"Front Immunol"},{"key":"1302_CR11","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1159\/000250839","volume":"1574","author":"T Fredriksson","year":"1978","unstructured":"Fredriksson T, Pettersson U. Severe psoriasis\u2013oral therapy with a new retinoid. Dermatologica. 1978;1574:238\u201344. https:\/\/doi.org\/10.1159\/000250839.","journal-title":"Dermatologica"},{"key":"1302_CR12","unstructured":"Hanover L. Is using PASI 100 realistic in a real-life setting? 2021. https:\/\/www.ajmc.com\/view\/is-using-pasi-100-realistic-in-a-real-life-setting-. Accessed 31 Oct 2024"},{"key":"1302_CR13","unstructured":"Heymann WR. PASI 100 and the Perfection Paradox 2016. http:\/\/www.coppoladelecuador.com\/pasi-100-and-the-perfection-paradox.html. Accessed 31 Oct 2024"},{"key":"1302_CR14","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1080\/09546634.2021.1890683","volume":"333","author":"I Belinchon Romero","year":"2022","unstructured":"Belinchon Romero I, Dauden E, Ferrandiz Foraster C, et al. PASI\u00a0100 response rates in moderate to severe psoriasis: a systematic literature review and analysis of clinical practice guidelines. J Dermatol Treat. 2022;333:1661\u20139. https:\/\/doi.org\/10.1080\/09546634.2021.1890683.","journal-title":"J Dermatol Treat"},{"key":"1302_CR15","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1080\/09546634.2016.1214667","volume":"283","author":"AW Armstrong","year":"2017","unstructured":"Armstrong AW, Feldman SR, Korman NJ, et al. Assessing the overall benefit of a medication: cumulative benefit of secukinumab over time in patients with moderate-to-severe plaque psoriasis. J Dermatol Treat. 2017;283:200\u20135. https:\/\/doi.org\/10.1080\/09546634.2016.1214667.","journal-title":"J Dermatol Treat"},{"key":"1302_CR16","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s13555-021-00647-0","volume":"121","author":"AW Armstrong","year":"2022","unstructured":"Armstrong AW, Soliman AM, Betts KA, et al. Long-term benefit-risk profiles of treatments for moderate-to-severe plaque psoriasis: a network meta-analysis. Dermatol Ther (Heidelb). 2022;121:167\u201384. https:\/\/doi.org\/10.1007\/s13555-021-00647-0.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1302_CR17","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1007\/s13555-022-00760-8","volume":"128","author":"A Armstrong","year":"2022","unstructured":"Armstrong A, Fahrbach K, Leonardi C, et al. Efficacy of bimekizumab and other biologics in moderate to severe plaque psoriasis: a systematic literature review and a network meta-analysis. Dermatol Ther (Heidelb). 2022;128:1777\u201392. https:\/\/doi.org\/10.1007\/s13555-022-00760-8.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1302_CR18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2102383","author":"K Reich","year":"2021","unstructured":"Reich K, Warren RB, Lebwohl M. Bimekizumab versus secukinumab in plaque psoriasis. N Engl J Med. 2021. https:\/\/doi.org\/10.1056\/NEJMoa2102383.","journal-title":"N Engl J Med"},{"key":"1302_CR19","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1056\/NEJMoa2102388","volume":"3852","author":"RB Warren","year":"2021","unstructured":"Warren RB, Blauvelt A, Bagel J, et al. Bimekizumab versus adalimumab in plaque psoriasis. N Engl J Med. 2021;3852:130\u201341. https:\/\/doi.org\/10.1056\/NEJMoa2102388.","journal-title":"N Engl J Med"},{"key":"1302_CR20","unstructured":"Higgins J, TJ CJ, Cumpston M, Li T, Page M, Welch V. Cochrane handbook for systematic reviews of interventions version 6.2 (updated August 2023): Cochrane; 2023."},{"key":"1302_CR21","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13643-021-01626-4","volume":"101","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst Rev. 2021;101:89. https:\/\/doi.org\/10.1186\/s13643-021-01626-4.","journal-title":"Syst Rev"},{"key":"1302_CR22","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366: l4898. https:\/\/doi.org\/10.1136\/bmj.l4898.","journal-title":"BMJ"},{"key":"1302_CR23","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1111\/jdv.15277","volume":"332","author":"LM Sawyer","year":"2019","unstructured":"Sawyer LM, Cornic L, Levin L, Gibbons C, M\u00f8ller AH, Jemec GB. Long-term efficacy of novel therapies in moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis of PASI response. J Eur Acad Dermatol Venereol. 2019;332:355\u201366. https:\/\/doi.org\/10.1111\/jdv.15277.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1302_CR24","unstructured":"Dias S, Welton NJ, Sutton AJ, Ades AE. Nice DSU technical support document 2: a generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials 2016. https:\/\/www.sheffield.ac.uk\/media\/34176\/download?attachment. Accessed 31 Oct 2024"},{"key":"1302_CR25","unstructured":"Borman I. Digitizeit 2.5; Bormisoft: Braunschweig, Germany. 2022 https:\/\/www.digitizeit.xyz\/. Accessed 31 Oct 2024"},{"key":"1302_CR26","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/S0140-6736(19)31773-8","volume":"39410201","author":"K Reich","year":"2019","unstructured":"Reich K, Armstrong AW, Langley RG, et al. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase\u00a03, randomised controlled trial. Lancet. 2019;39410201:831\u20139. https:\/\/doi.org\/10.1016\/S0140-6736(19)31773-8.","journal-title":"Lancet"},{"key":"1302_CR27","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.jaad.2016.11.041","volume":"763","author":"A Blauvelt","year":"2017","unstructured":"Blauvelt A, Papp KA, Griffiths CE, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase\u00a0III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol. 2017;763:405\u201317. https:\/\/doi.org\/10.1016\/j.jaad.2016.11.041.","journal-title":"J Am Acad Dermatol"},{"key":"1302_CR28","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1002\/jrsm.1373","volume":"104","author":"RK Owen","year":"2019","unstructured":"Owen RK, Bradbury N, Xin Y, Cooper N, Sutton A. MetaInsight: an interactive web-based tool for analyzing, interrogating, and visualizing network meta-analyses using R-shiny and netmeta. Res Synth Methods. 2019;104:569\u201381. https:\/\/doi.org\/10.1002\/jrsm.1373.","journal-title":"Res Synth Methods"},{"key":"1302_CR29","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1007\/s13555-021-00602-z","volume":"116","author":"K Fahrbach","year":"2021","unstructured":"Fahrbach K, Sarri G, Phillippo DM, et al. Short-term efficacy of biologic therapies in moderate-to-severe plaque psoriasis: a systematic literature review and an enhanced multinomial network meta-analysis. Dermatol Ther (Heidelb). 2021;116:1965\u201398. https:\/\/doi.org\/10.1007\/s13555-021-00602-z.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1302_CR30","unstructured":"Dias S, Welton NJ, Sutton AJ, Caldwell DM, Lu G, Ades AE. NICE DSU technical support document 4: inconsistency in networks of evidence based on randomised controlled trials 2014. https:\/\/www.sheffield.ac.uk\/media\/34181\/download?attachment. Accessed 31 Oct 2024"},{"key":"1302_CR31","unstructured":"Plummer M. JAGS: a program for analysis of Bayesian graphical models using Gibbs sampling. 3rd international workshop on distributed statistical computing (DSC 2003); Vienna, Austria. 2003;124."},{"key":"1302_CR32","doi-asserted-by":"publisher","first-page":"3049","DOI":"10.1002\/sim.3680","volume":"2825","author":"D Lunn","year":"2009","unstructured":"Lunn D, Spiegelhalter D, Thomas A, Best N. The BUGS project: evolution, critique and future directions. Stat Med. 2009;2825:3049\u201367. https:\/\/doi.org\/10.1002\/sim.3680.","journal-title":"Stat Med"},{"key":"1302_CR33","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/j.jid.2018.10.042","volume":"1395","author":"E von Stebut","year":"2019","unstructured":"von Stebut E, Reich K, Thaci D, et al. Impact of secukinumab on endothelial dysfunction and other cardiovascular disease parameters in psoriasis patients over 52\u00a0weeks. J Invest Dermatol. 2019;1395:1054\u201362. https:\/\/doi.org\/10.1016\/j.jid.2018.10.042.","journal-title":"J Invest Dermatol"},{"key":"1302_CR34","doi-asserted-by":"publisher","first-page":"AB38","DOI":"10.1016\/j.jaad.2020.06.239","volume":"83","author":"JG Krueger","year":"2020","unstructured":"Krueger JG, Pariser D, et al. 15354 Response to treatment with secukinumab in obese patients with moderate to severe psoriasis. J Am Acad Dermatol. 2020;83:AB38.","journal-title":"J Am Acad Dermatol"},{"issue":"Suppl. 1","key":"1302_CR35","first-page":"S26","volume":"14","author":"K Papp","year":"2021","unstructured":"Papp K, Warren R, Green L, et al. Efficacy and safety of mirikizumab versus secukinumab and placebo in the treatment of moderate-to-severe psoriasis: 52-week results from OASIS-2, a multicenter, randomized, double-blind study. J Clin Aesthet Dermatol. 2021;14(Suppl. 1):S26.","journal-title":"J Clin Aesthet Dermatol"},{"key":"1302_CR36","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/s13555-022-00690-5","volume":"123","author":"A Blauvelt","year":"2022","unstructured":"Blauvelt A, Gooderham M, Griffiths CEM, et al. Cumulative clinical benefits of biologics in the treatment of patients with moderate-to-severe psoriasis over 1\u00a0year: a network meta-analysis. Dermatol Ther (Heidelb). 2022;123:727\u201340. https:\/\/doi.org\/10.1007\/s13555-022-00690-5.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1302_CR37","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1080\/09546634.2020.1743811","volume":"331","author":"N Yasmeen","year":"2022","unstructured":"Yasmeen N, Sawyer LM, Malottki K, Levin LA, Didriksen Apol E, Jemec GB. Targeted therapies for patients with moderate-to-severe psoriasis: a systematic review and network meta-analysis of PASI response at 1\u00a0year. J Dermatolog Treat. 2022;331:204\u201318. https:\/\/doi.org\/10.1080\/09546634.2020.1743811.","journal-title":"J Dermatolog Treat"},{"key":"1302_CR38","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.jaad.2021.02.057","volume":"853","author":"NH Shear","year":"2021","unstructured":"Shear NH, Betts KA, Soliman AM, et al. Comparative safety and benefit-risk profile of biologics and oral treatment for moderate-to-severe plaque psoriasis: a network meta-analysis of clinical trial data. J Am Acad Dermatol. 2021;853:572\u201381. https:\/\/doi.org\/10.1016\/j.jaad.2021.02.057.","journal-title":"J Am Acad Dermatol"},{"key":"1302_CR39","doi-asserted-by":"publisher","first-page":"CD011535","DOI":"10.1002\/14651858.CD011535.pub5","volume":"55","author":"E Sbidian","year":"2022","unstructured":"Sbidian E, Chaimani A, Garcia-Doval I, et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev. 2022;55:CD011535. https:\/\/doi.org\/10.1002\/14651858.CD011535.pub5.","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01302-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-024-01302-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01302-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T03:17:34Z","timestamp":1731467854000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-024-01302-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":39,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["1302"],"URL":"https:\/\/doi.org\/10.1007\/s13555-024-01302-0","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"24 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Richard B. Warren declares receiving consulting fees from AbbVie, Almirall, Amgen, Arena, Astellas, Avillion, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly and Company, GSK, Janssen, LEO Pharma, Novartis, Pfizer, Sanofi and UCB Pharma. He also declares receiving research grants to his institution from AbbVie, Almirall, Janssen, LEO Pharma, Novartis and UCB Pharma, and honoraria from Astellas, DiCE, GSK and Union Therapeutics. Richard B. Warren is an Editor-in-Chief of<i> Dermatology and Therapy<\/i>. Richard B. Warren was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Kerry Donnelly, Sandeep Kiri, Vanessa Taieb are employees and shareholders of UCB Pharma. Mahmoud Slim, Kyle Fahrbach, Marissa Betts, Binod Neupane are employed by Evidera, a part of Thermo Fisher Scientific. April Armstrong has served as a research investigator and\/or scientific advisor to AbbVie, Almirall, Arcutis, ASLAN, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant, Dermira, Eli Lilly and Company, EPI, Incyte, Janssen, LEO Pharma, Nimbus, Novartis, Ortho Dermatologics, Pfizer, Regeneron, Sun Pharma, Sanofi and UCB Pharma.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}